Cite
HARVARD Citation
Nashan, B. et al. (n.d.). PHASE 2 STUDY DESIGN EVALUATING EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF THE ANTI-CD40 MONOCLONAL ANTIBODY CFZ533 (ISCALIMAB) IN DE NOVO LIVER TRANSPLANT RECIPIENTS. Transplantation. 104 (3), p. . [Online].